Hong Kong · Delayed Price · Currency is HKD Gaush Meditech Statistics
Total Valuation
Gaush Meditech has a market cap or net worth of HKD 636.44 million. The enterprise value is 706.27 million.
| Market Cap | 636.44M |
| Enterprise Value | 706.27M |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Gaush Meditech has 141.59 million shares outstanding. The number of shares has decreased by -2.21% in one year.
| Current Share Class | 141.59M |
| Shares Outstanding | 141.59M |
| Shares Change (YoY) | -2.21% |
| Shares Change (QoQ) | -0.89% |
| Owned by Insiders (%) | 45.68% |
| Owned by Institutions (%) | 0.20% |
| Float | 48.32M |
Valuation Ratios
The trailing PE ratio is 7.41.
| PE Ratio | 7.41 |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 1.21 |
| P/FCF Ratio | 3.94 |
| P/OCF Ratio | 3.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.48, with an EV/FCF ratio of 4.37.
| EV / Earnings | 8.10 |
| EV / Sales | 0.46 |
| EV / EBITDA | 3.48 |
| EV / EBIT | 7.07 |
| EV / FCF | 4.37 |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.35 |
| Quick Ratio | 1.20 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 2.29 |
| Debt / FCF | 2.87 |
| Interest Coverage | 5.58 |
Financial Efficiency
Return on equity (ROE) is 4.22% and return on invested capital (ROIC) is 4.21%.
| Return on Equity (ROE) | 4.22% |
| Return on Assets (ROA) | 2.15% |
| Return on Invested Capital (ROIC) | 4.21% |
| Return on Capital Employed (ROCE) | 4.27% |
| Weighted Average Cost of Capital (WACC) | 3.83% |
| Revenue Per Employee | 1.72M |
| Profits Per Employee | 97,919 |
| Employee Count | 890 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, Gaush Meditech has paid 16.51 million in taxes.
| Income Tax | 16.51M |
| Effective Tax Rate | 16.89% |
Stock Price Statistics
The stock price has decreased by -50.87% in the last 52 weeks. The beta is 0.01, so Gaush Meditech's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | -50.87% |
| 50-Day Moving Average | 4.71 |
| 200-Day Moving Average | 5.73 |
| Relative Strength Index (RSI) | 45.41 |
| Average Volume (20 Days) | 14,950 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gaush Meditech had revenue of HKD 1.53 billion and earned 87.15 million in profits. Earnings per share was 0.61.
| Revenue | 1.53B |
| Gross Profit | 689.88M |
| Operating Income | 99.95M |
| Pretax Income | 97.74M |
| Net Income | 87.15M |
| EBITDA | 176.05M |
| EBIT | 99.95M |
| Earnings Per Share (EPS) | 0.61 |
Balance Sheet
The company has 407.90 million in cash and 464.75 million in debt, with a net cash position of -56.86 million or -0.40 per share.
| Cash & Cash Equivalents | 407.90M |
| Total Debt | 464.75M |
| Net Cash | -56.86M |
| Net Cash Per Share | -0.40 |
| Equity (Book Value) | 1.92B |
| Book Value Per Share | 13.45 |
| Working Capital | 660.21M |
Cash Flow
In the last 12 months, operating cash flow was 189.32 million and capital expenditures -27.66 million, giving a free cash flow of 161.66 million.
| Operating Cash Flow | 189.32M |
| Capital Expenditures | -27.66M |
| Depreciation & Amortization | 77.15M |
| Net Borrowing | -84.76M |
| Free Cash Flow | 161.66M |
| FCF Per Share | 1.14 |
Margins
Gross margin is 45.19%, with operating and profit margins of 6.55% and 5.71%.
| Gross Margin | 45.19% |
| Operating Margin | 6.55% |
| Pretax Margin | 6.40% |
| Profit Margin | 5.71% |
| EBITDA Margin | 11.53% |
| EBIT Margin | 6.55% |
| FCF Margin | 10.44% |
Dividends & Yields
Gaush Meditech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 52.69% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.21% |
| Shareholder Yield | 2.21% |
| Earnings Yield | 13.69% |
| FCF Yield | 25.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gaush Meditech has an Altman Z-Score of 1.42 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.42 |
| Piotroski F-Score | 5 |